Roche announced that the European Commission has approved Perjeta in combination with Herceptin and chemotherapy for post-surgery treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. High risk of recurrence is defined as lymph node-positive or hormone receptor-negative disease. The Perjeta-based regimen should be administered for a total of one year as part of a complete regimen for eBC and regardless of the timing of surgery. “Despite advances in the treatment of HER2-positive early breast cancer, many people still have a recurrence and progress to an incurable stage. In the early breast cancer setting, where the ultimate goal is cure, it is critical that we continue building on existing therapies,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development. “Today’s approval is great news, as we believe the Perjeta-based regimen has the potential to make a significant impact on the lives of people with HER2-positive early breast cancer who are at high risk of recurrence. We are committed to working with EU member states to ensure the Perjeta-based regimen is available to eligible patients as soon as possible.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.